AR072198A1 - Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen - Google Patents
Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR072198A1 AR072198A1 ARP090102238A ARP090102238A AR072198A1 AR 072198 A1 AR072198 A1 AR 072198A1 AR P090102238 A ARP090102238 A AR P090102238A AR P090102238 A ARP090102238 A AR P090102238A AR 072198 A1 AR072198 A1 AR 072198A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- haloalkyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan derivados de isoquinolona de la formula general 1. Los compuestos son antagonistas de NK3 y son utiles para el tratamiento por ejemplo de la psicosis y la esquizofrenia. Reivindicacion 1: Un compuesto de acuerdo con la formula 1 en donde A representa N, CH o CR1; cada R1 independientemente representa hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -C(O)-alquilo C1-6, -C(O)-alquenilo C2-6, -C(O)-alquinilo C2-6, -C(O)-O-alquilo C1-6, -C(O)-O-alquenilo C2-6, -C(O)-O-alquinilo C2-6 o fenilo, en donde dicho fenilo, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 est opcionalmente sustituido con uno o m s sustituyentes seleccionados de halogeno, hidroxilo, haloalquilo C1-6, nitro, alcoxi C1-6, y NR2R3; X representa hidrogeno, alquilo C1-6 o -CraRb-X', en donde X' representa un resto monoc¡clico saturado que tiene 5-6 tomos en el anillo uno de los cuales es N y en donde uno o dos tomos del anillo adicionales pueden ser un hetero tomo seleccionado de N, O y S, dicho anillo monoc¡clico puede estar sustituido con uno o m s sustituyentes W, en donde W se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, o (=O); Ra y Rb representan cada uno individualmente hidrogeno, -CH3 o halogeno; Y representa un resto heteroarom tico que tiene 5-6 tomos en el anillo, en donde 1-4 de dichos tomos del anillo se seleccionan de N, O y S, dicho resto heteroarom tico puede opcionalmente estar benzofusionado, y dicho resto heteroarom tico puede estar sustituido con uno o m s sustituyentes Z, en donde Z se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, ciano, halogeno, hidroxi, alcoxi C1-6, haloalquilo C1-6, y NR2R3 en donde cada uno de R2 y R3 independientemente representan hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxialquilo C1-6, o haloalquilo C1-6; cada uno de R4-R8 y R9-R12 independientemente representan hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, NR2R3, hidroxi, ciano, nitro, alcoxi C1-6, haloalquilo C1-6 o hidroxialquilo C1-6; y sales farmaceuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200800859 | 2008-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072198A1 true AR072198A1 (es) | 2010-08-11 |
Family
ID=40941946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102238A AR072198A1 (es) | 2008-06-23 | 2009-06-19 | Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen |
Country Status (17)
Country | Link |
---|---|
US (1) | US8415356B2 (es) |
EP (1) | EP2313391B1 (es) |
JP (1) | JP2011525517A (es) |
KR (1) | KR20110026429A (es) |
CN (1) | CN102123998A (es) |
AR (1) | AR072198A1 (es) |
AU (1) | AU2009264365A1 (es) |
BR (1) | BRPI0914182A2 (es) |
CA (1) | CA2728283A1 (es) |
CO (1) | CO6280532A2 (es) |
EA (1) | EA201170074A1 (es) |
ES (1) | ES2401059T3 (es) |
IL (1) | IL209663A0 (es) |
MX (1) | MX2010013868A (es) |
NZ (1) | NZ590154A (es) |
TW (1) | TW201000458A (es) |
WO (1) | WO2009156339A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8242134B2 (en) | 2008-09-15 | 2012-08-14 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2010045948A1 (en) | 2008-10-20 | 2010-04-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
TW201144311A (en) * | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
US20110224247A1 (en) * | 2010-03-12 | 2011-09-15 | H. Lundbeck A/S | Azaisoquinolinone derivatives as nk3 antagonists |
WO2012035078A1 (en) * | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
CN108484591B (zh) * | 2018-05-28 | 2019-07-02 | 西安培华学院 | 用于治疗阿尔茨海默症的化合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3664492B2 (ja) | 1994-05-27 | 2005-06-29 | スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ | タチキニン nk▲下3▼ 受容体アンタゴニストとしてのキノリン誘導体 |
GB0318727D0 (en) * | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
MXPA06001738A (es) | 2003-08-15 | 2006-05-12 | Lundbeck & Co As H | Derivados de ciclopropilo como antagonistas del receptor nk3. |
GB0425077D0 (en) | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425076D0 (en) | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
US20080200500A1 (en) | 2005-06-03 | 2008-08-21 | Astrazeneca Ab | Quinoline Derivatives as Nk3 Antagonists |
WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
BRPI0917245B8 (pt) | 2008-09-15 | 2021-05-25 | H Lundbeck As | compostos derivados de isoquinolinona e sua composição farmacêutica |
WO2010045948A1 (en) | 2008-10-20 | 2010-04-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
-
2009
- 2009-06-19 TW TW098120596A patent/TW201000458A/zh unknown
- 2009-06-19 US US12/997,282 patent/US8415356B2/en active Active
- 2009-06-19 NZ NZ590154A patent/NZ590154A/en not_active IP Right Cessation
- 2009-06-19 AU AU2009264365A patent/AU2009264365A1/en not_active Abandoned
- 2009-06-19 ES ES09769188T patent/ES2401059T3/es active Active
- 2009-06-19 BR BRPI0914182A patent/BRPI0914182A2/pt not_active IP Right Cessation
- 2009-06-19 CA CA2728283A patent/CA2728283A1/en not_active Abandoned
- 2009-06-19 CN CN2009801322014A patent/CN102123998A/zh active Pending
- 2009-06-19 MX MX2010013868A patent/MX2010013868A/es not_active Application Discontinuation
- 2009-06-19 KR KR1020107028730A patent/KR20110026429A/ko not_active Application Discontinuation
- 2009-06-19 JP JP2011515321A patent/JP2011525517A/ja not_active Withdrawn
- 2009-06-19 EP EP09769188A patent/EP2313391B1/en active Active
- 2009-06-19 EA EA201170074A patent/EA201170074A1/ru unknown
- 2009-06-19 AR ARP090102238A patent/AR072198A1/es unknown
- 2009-06-19 WO PCT/EP2009/057660 patent/WO2009156339A1/en active Application Filing
-
2010
- 2010-11-30 IL IL209663A patent/IL209663A0/en unknown
- 2010-12-23 CO CO10161456A patent/CO6280532A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ590154A (en) | 2012-05-25 |
WO2009156339A1 (en) | 2009-12-30 |
CN102123998A (zh) | 2011-07-13 |
MX2010013868A (es) | 2011-02-24 |
US20110130407A1 (en) | 2011-06-02 |
EP2313391A1 (en) | 2011-04-27 |
KR20110026429A (ko) | 2011-03-15 |
US8415356B2 (en) | 2013-04-09 |
BRPI0914182A2 (pt) | 2019-09-24 |
JP2011525517A (ja) | 2011-09-22 |
CO6280532A2 (es) | 2011-05-20 |
CA2728283A1 (en) | 2009-12-30 |
IL209663A0 (en) | 2011-02-28 |
EA201170074A1 (ru) | 2011-10-31 |
EP2313391B1 (en) | 2012-12-26 |
ES2401059T3 (es) | 2013-04-16 |
AU2009264365A1 (en) | 2009-12-30 |
TW201000458A (en) | 2010-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072198A1 (es) | Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
CO6351781A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
PE20131197A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen | |
AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
AR061372A1 (es) | Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
ECSP066773A (es) | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos | |
PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
AR060506A1 (es) | Compuestos organicos | |
AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
AR040546A1 (es) | Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos | |
AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
MX2009013626A (es) | DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE. | |
AR073891A1 (es) | Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades. | |
AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |